Document Detail


Mechanism of the uricosuric action of E3040, a drug used to treat inflammatory bowel disease II: study using DBA/2N mice.
MedLine Citation:
PMID:  10594872     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In the initial phase of clinical studies, it was shown that E3040, a new type of anti-inflammatory drug, reduced plasma uric acid levels. The present study describes a comparison of the excretion of uric acid in the proximal tubules of the kidney after administration of E3040 and its conjugates, sulphate and glucuronide, with that of other general uricosuric agents in DBA/2N mice. The aim of this investigation was to elucidate the mechanism for the uricosuric action of E3040. It was found that E3040 increased the excretion rate of uric acid in a dose-dependent manner, and the excretion rates following 10 and 50 mg/kg doses were significantly greater than that of the control group. The paradoxical effect observed with probenecid was not seen in the E3040 dose-response curve for the uric acid excretion rate. Neither E3040-sulphate nor E3040-glucuronide increased the excretion rate of uric acid significantly, even at a high dose, such as 200 mg/kg. In the pyrazinoic acid suppression test, the uric acid excretion rate after concomitant administration of E3040 and pyrazinoic acid was significantly higher than that after administration of pyrazinoic acid alone, and the rate after concomitant administration was 30% of the level after administration of E3040 alone. The change in the excretion rate of uric acid after concomitant administration of E3040 and pyrazinoic acid was similar to that of AA193, a selective inhibitor of the presecretory reabsorption of uric acid. From these results, it appears that E3040 may exert its uricosuric action by reducing the presecretory reabsorption of uric acid rather than increasing its secretion.
Authors:
H Yamada; H Kotaki; H Furitsu; Y Sawada; T Iga
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Biopharmaceutics & drug disposition     Volume:  20     ISSN:  0142-2782     ISO Abbreviation:  Biopharm Drug Dispos     Publication Date:  1999 Jul 
Date Detail:
Created Date:  2000-02-07     Completed Date:  2000-02-07     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7911226     Medline TA:  Biopharm Drug Dispos     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  271-6     Citation Subset:  IM    
Copyright Information:
Copyright 1999 John Wiley & Sons, Ltd.
Affiliation:
Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo 1080071, Japan. hami-tky@umin.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Benzothiazoles
Gastrointestinal Agents / pharmacology*
Inflammatory Bowel Diseases / drug therapy*
Male
Mice
Mice, Inbred DBA
Pyrazinamide / analogs & derivatives,  pharmacology
Pyridines / pharmacokinetics,  pharmacology*
Thiazoles / pharmacokinetics,  pharmacology*
Uric Acid / urine
Uricosuric Agents / pharmacology*
Chemical
Reg. No./Substance:
0/Benzothiazoles; 0/Gastrointestinal Agents; 0/Pyridines; 0/Thiazoles; 0/Uricosuric Agents; 145096-30-6/E 3040; 69-93-2/Uric Acid; 98-96-4/Pyrazinamide; 98-97-5/pyrazinoic acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Metabolic kinetics of p-aminobenzoic acid in rabbits.
Next Document:  Mosaic trisomy 7 in a patient with pigmentary abnormalities.